Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 16 of 16 entries
View as:

Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01924819 Org: User:
Start: 09/30/09 End: 12/31/26 Due: 12/31/27

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05694936 Org: User:
Start: 01/23/23 End: 09/30/24 Due: 09/30/25

The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00294359 Org: User:
Start: 06/30/05 End: 07/31/07 Due: 07/31/08

A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study

Phase: N/A Priority: Normal
NCT ID: NCT06290505 Org: User:
Start: 12/08/21 End: 07/31/29 Due: 07/31/30

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02773524 Org: User:
Start: 11/30/16 End: 12/31/22 Due: 12/31/23

RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05862051 Org: User:
Start: 12/14/21 End: 06/14/25 Due: 06/14/26

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05042128 Org: User:
Start: 04/13/22 End: 10/01/25 Due: 10/01/26

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03647839 Org: User:
Start: 09/06/18 End: 04/09/21 Due: 04/09/22

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06094140 Org: User:
Start: 05/20/22 End: 06/30/26 Due: 06/30/27

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Phase: N/A Priority: Normal
NCT ID: NCT06441747 Org: User:
Start: 09/23/24 End: 08/31/28 Due: 08/31/29

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Phase: N/A Priority: Normal
NCT ID: NCT06345079 Org: User:
Start: 10/14/24 End: 06/30/28 Due: 06/30/29

MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

Phase: N/A Priority: Normal
NCT ID: NCT04089150 Org: User:
Start: 10/01/19 End: 08/30/23 Due: 08/30/24

Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study

Phase: N/A Priority: Normal
NCT ID: NCT02358356 Org: User:
Start: 11/30/15 End: 10/31/21 Due: 10/31/22

RegoNivo vs Standard of Care Chemotherapy in AGOC

Phase: N/A Priority: Normal
NCT ID: NCT04879368 Org: User:
Start: 06/01/21 End: 06/01/26 Due: 06/01/27

Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06604533 Org: User:
Start: 11/30/24 End: 11/30/27 Due: 11/30/28

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)

Phase: N/A Priority: Normal
NCT ID: NCT02365441 Org: User:
Start: 06/30/15 End: 12/31/23 Due: 12/31/24